CJC-1295 No DAC vs Tesamorelin: what is the difference?
CJC-1295 No DAC and tesamorelin are distinct GHRH-related research materials, not alternate names for one peptide. Published studies of tesamorelin and long-acting CJC-1295 cannot automatically describe a vial labelled No DAC. For UAE procurement, compare the specified molecular form, the material studied and the documentation for the actual lot offered.
Quick answer for research buyers
| Check | Why it matters |
| — | — |
| Exact identity | A shared research category does not establish the same sequence or molecular form. |
| Study-to-material match | A paper about long-acting CJC-1295 is not automatically evidence about No DAC. |
| Lot-matched testing | A catalogue purity claim cannot replace documentation for the batch being supplied. |
| UAE delivery eligibility | Checkout availability does not establish import permission or customs clearance. |
This is a procurement and evidence-traceability comparison, not a ranking of biological effects. It is intended for organisations assessing materials for non-clinical research.
How was this comparison made?
Evidence review as of February 2025: This guide compares the molecular-form descriptions in the cited CJC-1295 and tesamorelin publications, the scope of the US tesamorelin label, and the questions a buyer can reasonably put to a supplier. It does not treat a product listing as proof that its material matches a published preparation. No direct head-to-head study of the exact materials named in this comparison was identified in the references below; the absence of one from this review is not proof that none exists.
Market details are different from published evidence. Stock, lot availability, prices, delivery routes and payment options can change. Confirm those details at the time of a Dubai, wider UAE or GCC enquiry rather than treating this guide as a live inventory or regulatory notice.
Why does “No DAC” matter when reading CJC-1295 studies?
DAC refers to a drug-affinity-complex modification associated with the long-acting CJC-1295 preparation described in frequently cited human research. A material sold as CJC-1295 No DAC is commonly described by suppliers as Modified GRF(1-29), without that modification. Those names should prompt a specification check, not serve as independent verification of a vial’s contents.
Teichman and colleagues studied a long-acting CJC-1295 preparation. Their publication should not be cited as a study of a separately marketed No-DAC material merely because both listings contain “CJC-1295.” Ask for the offered material’s sequence or structural specification, stated DAC status and lot-level identity results. If the supplier cannot explain how its name maps to the specification, comparison with that publication remains unresolved.
Tesamorelin has its own published human research, including a study by Falutz and colleagues in a defined clinical population. The US DailyMed listing concerns a regulated prescription product; it does not verify the identity, quality, authorisation or research suitability of a separately supplied vial. Neither the tesamorelin literature nor the US label should be transferred to another material by analogy.
The practical distinction is simple: a publication can help identify what was studied. It cannot, on its own, identify what is in the lot a supplier will ship.
Which product fits a defined research requirement?
Start with the protocol’s material specification, not with an informal comparison of popularity or price. If the work requires a preparation described as Modified GRF(1-29) without DAC, the purchasing record should use that identity and request confirmation that the offered CJC-1295 No DAC lot matches it. If the work specifies tesamorelin, check the listing and lot documents against that specification instead. Do not substitute one for the other without an approved scientific and procurement review.
Record the reference paper, the preparation named in it, its study population or model, and the measured endpoints. Then record any differences between that preparation and the supplier’s specification. This is especially important when a catalogue description cites “CJC-1295 research” without saying which form was studied.
Neither product name answers a separate institutional question: whether the organisation is permitted to obtain that material for its proposed work. Keep scientific fit, supplier documentation and regulatory eligibility as three distinct checks.
What should a UAE buyer request with the lot?
A certificate of analysis (COA) is useful only to the extent that it describes the material and tests actually relevant to the order. An undated sample report or report for a different batch may illustrate a supplier’s testing format, but it is not evidence for the lot that will arrive.
- Lot linkage: Match the COA’s product identifier and batch number to the quotation, vial label and shipping paperwork. Ask which document will accompany the shipped lot if stock is allocated after payment.
- Identity: Check the stated sequence or molecular specification, relevant salt or counterion information where available, and explicit DAC status for a No-DAC listing. Ask what method supports the identity assignment; mass spectrometry can support a mass claim, while sequence-related claims may require additional appropriate analysis.
- Purity method: If the report gives an HPLC purity percentage, request the method or chromatogram where available. An HPLC area percentage describes a result under stated analytical conditions; it is not automatically an assay of peptide quantity per vial.
- Scope of other tests: Check whether a claimed test actually covers the characteristic you need. An identity result is not a sterility result, and a generic “tested” badge does not specify endotoxin, microbiological or residual-solvent testing.
- Report provenance: Look for the testing date, laboratory identity, methods and a way to connect a third-party report to the supplier’s lot. Ask for clarification if figures, names or dates conflict.
NOVA Labs’ lab-results page is a place to check for available reports; confirm that any report you use corresponds to the specific lot offered. A published report for another batch should not be presented as proof for a new one. These checks are about research procurement, not certification for human administration.
How do Dubai delivery, payment and support affect the decision?
In the UAE, procurement does not end at the product page. Ask the supplier whether the specific item and lot can be dispatched to your destination, how the shipment is packed for its stated storage and transit requirements, and whether tracking and a realistic dispatch window are available. UAE heat makes transit arrangements worth checking, but it does not justify assuming one universal temperature requirement for every peptide or formulation.
If a laboratory outside the UAE is ordering for another GCC destination, check that destination’s import and institutional requirements separately. A supplier’s GCC delivery statement or a successful checkout does not establish customs clearance. Likewise, research-use wording is not an import permit. An authorised institutional buyer should check the applicable rules for the material and intended non-clinical work with its compliance team and relevant authorities. The Emirates Drug Establishment is a starting point for current UAE federal regulatory information; other requirements may apply.
Before paying, confirm accepted payment methods, the currency and final charges, the recipient details needed for dispatch, and how the supplier handles an unavailable lot. Use the listed support channel to ask one consolidated question: can the supplier provide a lot-matched COA, clarify the molecular form, and confirm the shipping conditions for the destination? If WhatsApp support is offered, retain the written answer with the purchase record; do not assume a chat response replaces formal documentation.
Bottom line
For this comparison, the decisive questions are whether the names identify the requested molecular forms, whether cited publications studied those forms, and whether the lot offered is adequately documented. Tesamorelin’s published record does not validate an unrelated research vial, and long-acting CJC-1295 research should not be assigned to No DAC by name alone.
For a qualified research enquiry, review the CJC-1295 No DAC listing or tesamorelin listing, then request current lot documentation and destination-specific dispatch details before ordering.
Research-use disclaimer: The materials discussed are for research purposes only, not for human consumption or administration. This article does not provide medical or regulatory approval advice.
References
- Teichman et al., study of long-acting CJC-1295 (PubMed).
- Falutz et al., tesamorelin study in a defined clinical population (PubMed).
- US National Library of Medicine, DailyMed search for tesamorelin prescribing information. US labelling is provided for product and evidence context, not UAE authorisation.
- Emirates Drug Establishment, official UAE regulatory information. Check current requirements with the relevant authority and your institution.
- Emirates Drug Establishment — Circular No. 46/2026, Guideline for Handling Peptide Products and Molecules
- FDA — December 4, 2024 Pharmacy Compounding Advisory Committee briefing document on CJC-1295-related substances
- DailyMed — EGRIFTA SV (tesamorelin) label, updated July 29, 2026
- Primary studies — Teichman et al., CJC-1295 in healthy adults (PubMed); Falutz et al., tesamorelin in HIV-associated abdominal fat (PubMed)
Frequently asked questions
What is the difference between CJC-1295 No DAC and tesamorelin?
They are distinct GHRH-related research materials with different molecular specifications and publication records. Check each offered lot’s identity rather than treating the names as interchangeable.
Does a human CJC-1295 study apply to CJC-1295 No DAC?
Not automatically. A frequently cited study examined a long-acting CJC-1295 preparation. Its findings should not be attributed to a separately marketed No-DAC material without establishing that the studied form matches it.
Has CJC-1295 No DAC been compared directly with tesamorelin?
No direct head-to-head study of those exact materials was identified in the references reviewed for this guide as of February 2025. That limited review cannot rule out other publications.
What should I check on a peptide COA for a UAE research order?
Match the COA to the offered lot and check the stated identity, methods, testing date and meaning of any HPLC purity figure. A COA does not establish import permission or suitability for human administration.
Can I order a research peptide for delivery to Dubai or another GCC destination?
Delivery availability depends on the supplier and destination. Before ordering, confirm stock, shipping conditions and payment details, and have your organisation check applicable import and research requirements; checkout availability alone is not permission to import.
Nova Labs buyer tools
Ready to verify stock, testing and delivery?
Use the product page and lab report section to check availability, documentation, delivery timing and support before placing an order.
- COA / test-report checks
- UAE delivery context
- Cold-chain handling
- COD and card payment options
- WhatsApp support



